Chronic pain: assessment and management
In development [GID-NG10069] Expected publication date: TBC
Search results
513 results
-
-
Shared decision making
In development [GID-NG10120] Expected publication date: 14 April 2021
-
Integrated health and care for people who are homeless through being roofless
In development [GID-NG10170] Expected publication date: TBC
-
Heart valve disease presenting in adults: investigation and management
In development [GID-NG10122] Expected publication date: 20 May 2021
-
Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management
In development [GID-NG10149] Expected publication date: 17 February 2022
-
Head injury: assessment and early management
In development [GID-NG10164] Expected publication date: 02 December 2021
-
Multiple sclerosis in adults: management
In development [GID-NG10153] Expected publication date: 04 May 2022
-
Perioperative care in adults
In development [GID-NG10072] Expected publication date: 27 May 2020
-
Diabetes in pregnancy: management from preconception to the postnatal period
In development [GID-NG10158] Expected publication date: TBC
-
Joint replacement (primary): hip, knee and shoulder
In development [GID-NG10084] Expected publication date: 25 March 2020
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 09 November 2021
-
Epilepsies in children, young people and adults
In development [GID-NG10112] Expected publication date: 16 November 2021
-
Atrial fibrillation: management
In development [GID-NG10100] Expected publication date: 17 September 2020
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 15 December 2021
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 26 April 2021
-
Postnatal care
In development [GID-NG10070] Expected publication date: 25 November 2020
-
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404
In development [GID-TA10327] Expected publication date: 14 July 2021
-
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]
In development [GID-TA10381] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: 24 March 2021
-
Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]
In development [GID-TA10510] Expected publication date: TBC
-
Erenumab for preventing migraine [ID1188]
In development [GID-TA10302] Expected publication date: TBC
-
Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]
In development [GID-TA10565] Expected publication date: 16 December 2020
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: 11 November 2020
-
Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer [ID1140]
In development [GID-TA10181] Expected publication date: TBC
-
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]
In development [GID-TA10460] Expected publication date: TBC
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: 23 September 2020
-
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
In development [GID-TA10208] Expected publication date: TBC
-
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
In development [GID-TA10607] Expected publication date: TBC
-
Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Elotuzumab for multiple myeloma [ID966]
In development [GID-TA10134] Expected publication date: TBC
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
In development [GID-TA10342] Expected publication date: TBC
-
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]
In development [GID-TA10571] Expected publication date: 25 August 2021
-
Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: TBC
-
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]
In development [GID-TA10569] Expected publication date: TBC
-
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]
In development [GID-TA10568] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]
In development [GID-TA10580] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]
In development [GID-TA10578] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
In development [GID-TA10576] Expected publication date: TBC
-
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
In development [GID-TA10575] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: 16 December 2020
-
Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586
In development [GID-TA10514] Expected publication date: 12 August 2020
-
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
In development [GID-TA10527] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
In development [GID-TA10589] Expected publication date: TBC
-
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development [GID-TA10573] Expected publication date: TBC
-
Nivolumab with cisplatin and fluorouracil for untreated advanced oesophageal squamous cell carcinoma [ID2712]
In development [GID-TA10572] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
In development [GID-TA10512] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC